Actelion Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACTELION, and when can generic versions of ACTELION drugs launch?
ACTELION has eight approved drugs.
There are fifteen US patents protecting ACTELION drugs.
There are two hundred and forty-six patent family members on ACTELION drugs in thirty-nine countries and thirty-four supplementary protection certificates in seventeen countries.
Summary for Actelion
| International Patents: | 246 |
| US Patents: | 15 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 8 |
| PTAB Cases with Actelion as petitioner: | See PTAB cases with Actelion as petitioner |
Drugs and US Patents for Actelion
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-003 | Dec 21, 2015 | RX | Yes | No | 8,791,122 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | 9,284,280 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Actelion | VENTAVIS | iloprost | SOLUTION;INHALATION | 021779-003 | Aug 7, 2009 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Actelion
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Actelion | ZAVESCA | miglustat | CAPSULE;ORAL | 021348-001 | Jul 31, 2003 | 5,472,969 | ⤷ Try a Trial |
| Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-002 | Nov 20, 2001 | 5,292,740 | ⤷ Try a Trial |
| Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-001 | Nov 20, 2001 | 5,292,740 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACTELION drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2017-10-18 |
| ➤ Subscribe | for Oral Suspension | 32 mg | ➤ Subscribe | 2019-02-08 |
International Patents for Actelion Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200823198 | ⤷ Try a Trial |
| China | 1301973 | ⤷ Try a Trial |
| Croatia | P20120957 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Actelion Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1345920 | 300672 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MACITENTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220 |
| 1345920 | CR 2014 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MACITENTAN OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/13/893 20131227 |
| 1400518 | 122016000077 | Germany | ⤷ Try a Trial | PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
